Hochschulschrift
Identification of potential targets for palbociclib combination therapy in the context of MLL-rearranged acute myeloid leukemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Dimensions
-
30 cm
- Extent
-
140 Seiten, 10 ungezählte Seiten
- Language
-
Englisch
- Notes
-
Illustrationen, Diagramme
Ruperto-Carola University of Heidelberg, Dissertation, 2018
- Table of contents
- Rights
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Last update
- 11.06.2025, 1:48 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
Time of origin
- [2018]
Other Objects (12)
RNA binding proteins in MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Using genome editing to model MLL rearranged leukemias
MLL-r Leukemia
The role of EZH2 in CDK6 bockade-mediated differentiation in MLL-rearranged acute myeloid leukaemia
RNA binding proteins in MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Using genome editing to model MLL rearranged leukemias
MLL-r Leukemia
The role of EZH2 in CDK6 bockade-mediated differentiation in MLL-rearranged acute myeloid leukaemia
RNA binding proteins in MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Using genome editing to model MLL rearranged leukemias
MLL-r Leukemia